

CLAIMS

1. (Currently amended) A method of treating atypical depression secondary to pain (DSP) in an individual suffering from DSP, which comprises administering to the individual an effective amount of a dual norepinephrine serotonin reuptake inhibitor (NSRI) or triple reuptake inhibitor (TRI) selected from the group consisting of milnacipran, bicifadine, sibutramine, venlafaxine, duloxetine and pharmaceutically acceptable salts thereof, to alleviate at least one symptom of atypical depression.
2. (Currently amended) The method of claim 1 wherein the NSRI ~~has an NE: 5-HT reuptake inhibition ratio of about 1:1 to about 50:1~~ is milnacipran.
3. (Canceled)
4. (Canceled)
5. (Currently amended) The method of claim [4] 2 wherein the milnacipran is administered at a dosage of between 100 and 400 mg/day.
6. (Currently amended) The method of claim [4] 2 wherein the milnacipran is administered at a dosage of between 100 and 250 mg/day.
7. (Currently amended) The method of claim [1] 2 wherein the ~~inhibitor~~ milnacipran is administered two or more times per day.
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Withdrawn) The method of claim 1 wherein the inhibitor is a triple reuptake inhibitor blocking uptake of serotonin, noradrenaline, and dopamine.

12. (Previously Presented) The method of claim 1 wherein the DSP comprises atypical depression and either chronic pain or neuropathic pain.

13. (Previously Presented) The method of claim 12 wherein the DSP comprises chronic pain selected from the group consisting of lower back pain, atypical chest pain, headache, pelvic pain, myofascial face pain, abdominal pain, neck pain and chronic pain caused by a disease or condition.

14. (Previously Presented) A method of treating atypical depression secondary to pain (DSP) in an individual suffering from DSP, which comprises administering to the individual an effective amount of a dual norepinephrine serotonin reuptake inhibitor (NSRI) or triple reuptake inhibitor (TRI) selected from milnacipran, bicifadine, sibutramine, venlafaxine, duloxetine, and pharmaceutically acceptable salts thereof, to alleviate at least one symptom of atypical depression, wherein the DSP comprises atypical depression characterized by mood reactivity and neurovegetative symptoms present for more than about two weeks.

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Previously Presented) The method of claim 14, wherein the dual norepinephrine serotonin reuptake inhibitor (NSRI) is milnacipran, or a pharmaceutically acceptable salt thereof.

20. (Canceled)

21. (Canceled)